Selexis Announces Expansion of R&D License Agreement with Amgen
News Feb 22, 2013
Selexis SA has announced that Amgen has expanded their R&D License Agreement with Selexis to include an evaluation of the proprietary Selexis SURE CHO-M Cell Line™ for research and development.
Under the agreement, Amgen will be able to evaluate the SURE CHO-M Cell Line™ in conjunction with the Selexis SUREtech Vectors™ for improved R&D.
“Successful protein expression in R&D is dependent upon a cell line development platform that is robust, high-yielding and stable,” said Igor Fisch, Ph.D., President and CEO of Selexis.
Fisch continued, “Selexis is continually optimizing its proprietary cell line and technology platform to enable partners such as Amgen to make better R&D decisions by generating reliable data points faster and more cost efficiently. This current agreement is built on the long-standing relationship between our two companies since 2004.”
Concept Life Sciences and Alderley Analytical Partner to provide Bioanalytical and DMPK ServicesNews
Companies announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.READ MORE
BIA Separations appoints Pete Gagnon as Chief Scientific OfficerNews
Appointment will drive new product and applications development.READ MORE